Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH/ISH 2016 | Drug combinations in CLL: ibrutinib, idelalisib and more

Andrew Zelenetz • 18 Apr 2016
BSH/ISH 2016
Chronic Lymphocytic Leukemia Ibrutinib Idelalisib

Andrew Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, New York, NY discusses the mechanism of action of ibrutinib and idelalisib and further drug combinations under investigation in CLL. Both drugs impact the growth and survival of CLL cells but in a parallel way according to Dr Zelenetz. He further discusses various studies looking at combinations, such as idelalisib with BTK inhibitor ONO-4059, and PI3K delta inhibitor ME-401 with a novel BTK inhibitor.
Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland.

More from Andrew Zelenetz

Novel lymphoma targets and agents
Andrew Zelenetz et al. • 8 Sep 2017
16:39
iwNHL 2015 roundtable: The changing treatment landscape for non-Hodgkin lymphoma
Andrew Zelenetz et al. • 3 Oct 2015
5:20
m7-FLIPI identifies patients with early disease progression of FL after therapy
Andrew Zelenetz • 4 Dec 2015
4:51
Idelalisib plus bendamustine and rituximab improves the outcome of relapsed/refractory CLL
Andrew Zelenetz • 4 Dec 2015

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals